Shots:
- ABL Bio has secured a total of $55M, incl. $40M upfront & $15M in equity investment, from Eli Lilly under their ~$2.602B license, research & collaboration agreement
- Under the deal, ABL Bio & Eli Lilly are jointly advancing multiple therapeutic candidates across diverse modalities, leveraging ABL Bio’s Grabody platform for collaborative research & development
- The funding will support ABL Bio’s expansion of the Grabody platform into high-unmet-need areas such as obesity & muscle disorders, while advancing bispecific immuno-oncology combinations & next-generation ADC programs
Ref: PR newswire | Image: ABL Bio & Eli Lilly | Press Release
Related News: ABL Bio Licenses Grabody-B Brain Delivery Platform to GSK for ~$2.76B (£2.15B)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
